Key facts
- ClonOrgan’s last known valuation is $41.7M (Sep 2021).
- It has raised $8.3M; the latest was Later Stage VC in Sep 2025.
- Notable investors include YuanBio Venture Capital, Betta Pharmaceutical Biotechnology Fund, ChipBio, Luminous Ventures, Shenzhen Sangel Venture Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ClonOrgan
- ·The full record, as it builds
Funding rounds
No funding rounds for ClonOrgan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ClonOrgan
Developer of xenotransplantation technologies aims to advance clinical applications of gene-edited donor pigs. The company leverages China's largest herd of low-immunogenicity pigs, whole-industry-chain expertise, and transplantable organ R&D to serve the biomedical and healthcare sectors, enabling new therapeutic options for kidney, liver, heart, and other organ replacement.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2018
- Employees
- 30
- Website
- clonorgan.com/
- Ownership
- Privately Held (backing)
ClonOrgan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ClonOrgan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ClonOrgan in its N-PORT filings yet. We sweep new filings monthly.